Paclitaxel Injection Market: by Indication (Prostate cancer, breast cancer, non-small cell lung cancer, aids related Kaposi’s sarcoma, ovarian cancer, stomach cancer, cervical cancer, esophageal cancer, testicular cancer, lung cancer, pancreatic cancer and others), End user (Cancer Research centers, Hospital and Others) – Global Industry Analytics COVID-19 Business Impact, and Trends, 2019-2025

                                          
Abstract


The report covers forecast and analysis for the Paclitaxel Injection market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Paclitaxel Injection market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Paclitaxel Injection market on a global level. In order to give the users of this report a comprehensive view on the Paclitaxel Injection market, we have included a competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication, End-user, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

According to the report, global demand for Paclitaxel Injection Market was valued at approximately USD 2963.5 Million in 2018 and is expected to generate revenue of around USD 6628.6 Million by end of 2025, growing at a CAGR of around 12.19% between 2021 and 2026.

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. It is a class of antineoplastic drug sub-segment that is used to treat breast, lung, ovary, abdomen, cervix, and other cancer. Infection with Paclitaxel targets tubulin, which in the human cell is a small globular protein. Under the guidance of an oncologist with expertise in chemotherapy, it should be administered. If a person has some allergic condition, the doctor does not prescribe it. Always check which patient does not suffer from high or low-pressure issue until prescribing this drug physician. Paclitaxel injection has several side effects such as causing allergy, decreasing the number of WBCs and also causing problems with blood pressure.

Abraxane® is specifically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

The study provides a decisive view on the Paclitaxel Injection market by segmenting the market based on Indication, End user and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on Indication, the market is segmented into Prostate cancer, breast cancer, non-small cell lung cancer, aids related Kaposis sarcoma, ovarian cancer, stomach cancer, cervical cancer, esophageal cancer, testicular cancer, lung cancer, pancreatic cancer and others. According to the WHO, 723,000 deaths from stomach cancer and 521,000 deaths from breast cancer in 2012 alone. In the United States Estimated New Female Breast Cases in 2020 will be approximately 276,480 while New Stomach Cancer cases in 2020 will be approximately 27600.

Paclitaxel is used to treat both of these cancers, and rising cancer incidences would lead to increased use of this drug for treatment. Based on the End-user segment, the market is bifurcated into Cancer Research centers, Hospital and Others.

The geographical segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to the high incidence of cancer patients in this country, North America currently dominates the market. Nevertheless, because of rising cancer incidences, Europe and Asia Pacific are emerging markets.

The increasing incidence of cancer is the major driving force for this markets significant growth. Paclitaxel injection has better efficiency for cancer treatment than other drugs, besides that it is also readily available on the market that is responsible for this markets growth. Major players on the market for paclitaxel injection focus on developing better paclitaxel injection, which will be a remarkable opportunity for this market to grow. Many adverse effects such as blood clot, allergy, leucopenia, diarrhea, and weight loss may restrict the growth of the market for paclitaxel injection. The high cost of medication, which in low economic countries is less available, may also hamper the growth of the demand for paclitaxel injection.

Key players within global Paclitaxel Injection market include Abraxis Bio Science Inc., Celgene, Abbott Laboratories, Fresenius Kabi Oncology Ltd, Onco Therapies Ltd, Novasep, Sagent Pharmaceuticals,  WG Critical Care, LLC, Ivax Pharmaceuticals Incorporated, TEVA Canada Limited, Biolyse Pharma Corporation, Sterimax Inc,  amongst others.

The report segments global Paclitaxel Injection market as follows:

Global Paclitaxel Injection Market: Indication Segment Analysis

  
Prostate cancer
  
Breast cancer
  
Non-small cell lung cancer
  
AIDS related Kaposis sarcoma
  
Ovarian cancer
  
Stomach cancer
  
Cervical Cancer
  
Esophageal cancer
  
Testicular cancer
  
Lung cancer
  
Pancreatic cancer
  
Others

Global Paclitaxel Injection Market: End user Segment Analysis

  
Cancer Research centers
  
Hospital
  
Others

Global Paclitaxel Injection Market: Regional Segment Analysis

  
North America
  
Europe
  
Asia Pacific
  
Latin America
  
Middle East Asia and Africa

In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.

Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion. It is used on its own when other treatments have not worked or are not suitable. It is also used in combination with other cancer medicines: paclitaxel or docetaxel in metastatic gastric (stomach) cancer, in combination with cisplatin and either capecitabine or fluorouracil (other cancer medicines).

The cost for Herceptin intravenous powder in the US for injection of 150 mg is around $1,500 for a supply of 1 powder for injection.

UK trastuzumab market is size is close to US$96.2 Million in 2020.